Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Richard Muruve
Person

Richard Muruve

Tracked across 2 events · 12 articles · First seen Jul 17, 2026 · Last active Aug 11, 2026

Sentiment
5
Attention
2
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
0 0
Business
Arch Biopartners advances IL-32 CKD program
Impact: Richard Muruve, CEO of Arch Biopartners, commented on the research contract as an important step for the IL-32 program.
Jul 17, 2026 · 6 articles
2 10
Business
Arch Biopartners expands CS-AKI trial to US
Arch Biopartners Inc. announced on August 11, 2026 that it will expand its ongoing Phase II clinical trial of LSALT peptide, targeting cardiac surgery-associated acute kidney injury (CS-AKI), into the United States. The expansion follows…
Impact: Richard Muruve, CEO, is the spokesperson for the announcement, representing the company's leadership.
Aug 11, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Richard Muruve live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.